J Korean Acad Oral Maxillofac Radiol.  1997 Aug;27(2):91-104.

A study on the radiosensitivity and chemosensitivity of A-253 cell line in vitro

Affiliations
  • 1Department of Oral and Maxillofacial Radiology, College of Dentistry, Kyung Hee University, Korea.

Abstract

The purpose of this study was to aid in the prediction of tumor cell tolerance to radiotherapy and/or chemotherapy. For this study, cell surviving curves were obtained for human epidermoid carcinoma A-253 cell line using semiautomated MTT assay. 2, 4, 6, 8, 10 Gy were irradiated at a dose rate of 210 cGy/min using 60Co Irradiator ALDORADO 8. After irradiation, A-253 cell lines(2x10(4) cells/ml) were exposed to bleomycin or cisplatin for 1 hour. The viable cells were determined for each radiation dose with/without 2 ug/ml of drug at the 3rd day. And they were compared to control values. The results were obtained as follows: 1. The surviving curve with gentle slope was obtained after irradiation of 2, 4, 6, 8, 10 Gy on A-253 cell line. 2. The cytotoxicity of bleomycin or cisplatin at the concentration of 2 ug/ml was great on A-253 cell line. But, there was no significant difference between the cytotoxicity of bleomycin and that of cisplatin. 3. There were significant differences of surviving fractions after irradiation with 2 ug/ml of bleomycin compared with irradiation only on A-253 cell line. 4. There were significant differences of surviving fractions after irradiation with 2 ug/ml of cisplatin compared with irradiation only on A-253 cell line. 5. There were no significant differences of surviving fractions between the groups of irradiation with bleomycin and the groups of irradiation with cisplatin on A-253 cell line.


MeSH Terms

Bleomycin
Carcinoma, Squamous Cell
Cell Line*
Cisplatin
Drug Therapy
Humans
Radiation Tolerance*
Radiotherapy
Bleomycin
Cisplatin
Full Text Links
  • JKAOMR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr